Jonathan Zalevsky
Technik-/Wissenschafts-/F&E-Leiter bei NEKTAR THERAPEUTICS
Vermögen: 327 241 $ am 31.05.2024
Profil
Jonathan Zalevsky is currently a Director at ReAlta Life Sciences, Inc. He is also an Independent Director at Invea Therapeutics, Inc. since 2021.
Prior to his current positions, he served as the Chief Research & Development Officer at Nektar Therapeutics starting in 2015.
Previously, he worked at Takeda Pharmaceuticals U.S.A., Inc. as the Global VP & Head-Inflammation Drug Discovery Unit.
Dr. Zalevsky holds a doctorate degree from The University of California, San Francisco and an undergraduate degree from the University of Colorado Boulder.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEKTAR THERAPEUTICS
0,14% | 17.05.2024 | 257 670 ( 0,14% ) | 327 241 $ | 31.05.2024 |
Aktive Positionen von Jonathan Zalevsky
| Unternehmen | Position | Beginn |
|---|---|---|
| NEKTAR THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2015 |
ReAlta Life Sciences, Inc.
 ReAlta Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of immune system through PIC1 technology. The company was founded in 2018 and is headquartered in Norfolk, VA. | Direktor/Vorstandsmitglied | - |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Direktor/Vorstandsmitglied | 01.11.2021 |
Ehemalige bekannte Positionen von Jonathan Zalevsky
| Unternehmen | Position | Ende |
|---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Ausbildung von Jonathan Zalevsky
| University of Colorado Boulder | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
ReAlta Life Sciences, Inc.
ReAlta Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of immune system through PIC1 technology. The company was founded in 2018 and is headquartered in Norfolk, VA. | Commercial Services |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Health Technology |
